Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldn't Miss What That Could Signal

Key Points Johnson & Johnson announced plans to spin off its orthopedics business in late 2025. In early 2026, J&J was reported to be in talks with private equity firms about a sale. In late 2026, J&J was reported to be in talks with Apollo on a $20 billion deal. 10 stocks we like better than Johnson & Johnson › Wall Street goes through cycles in which companies buy assets to create diversified conglomerates, and then sell assets to streamline and focus. Right now, investors are rewarding companies for simplifying their operations and focusing their businesses. That's what Johnson & Johnson (NYSE: JNJ) has been doing. Here's what's been happening, why it's happening, and what it could mean for investors. This isn't Johnson & Johnson's first rodeo For many years, Johnson & Johnson was one of the most diversified healthcare companies an investor could own. Its business spanned over-the-counter consumer products, medical devices, and pharmaceuticals. The problem is that all of its divisions had very different business profiles. Diversification is something many investors cherish, but it can lead to slower decision-making and obscure the strong performance of faster-growing divisions. Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue » Image source: Getty Images. Wall Street has a strong preference for growth, so J&J decided to break up the conglomerate. The first major move was the spin-off of Kenvue (NYSE: KVUE) in 2023. This company owns J&J's former over-the-counter healthcare brands. This business was more similar to a consumer staples company than a healthcare company, so it was a fairly logical move. Kenvue is now being acquired by consumer-staples giant Kimberly Clark (NASDAQ: KMB) , which is seeking to diversify its business. The big story about J&J's spin-off of Kenvue, however, is that it allowed the company to focus on its higher-margin, higher-growth healthcare operations. The plan to spin off DePuy Synthes has the same goal and was announced in late 2025. However, spin-offs are difficult, and they aren't always as beneficial to the former parent as a sale. J&J starts talking to buyout firms So it wasn't much of a surprise to see reports in early 2026 that J&J was in discussions with buyout firms about DePuy Synthes. At that time, there were no firm details or solid leads about who was interested. But that changed recently, when it was reported that Apollo Global Management was considering buying the division for $20 billion. The benefit for Apollo is that it can put a large amount of capital to work in a reliable, highly respected business. That's not a bad outcome given the current market and economic uncertainties. For J&J, the benefits of selling DePuy Synthes to Apollo are twofold: simplicity and streamlining. Selling to Apollo will likely be far easier than a spinoff, and it will leave J&J with cash for other purposes, such as stock buybacks, debt reduction, or reinvestment in its business. That should please J&J shareholders. But the long-term benefit is still on the growth side of the ledger. This remains the core reason for the move. As J&J stated when it announced the spin-off, removing DePuy Synthes, an orthopedic company that makes products such as joint replacements, from its portfolio would help in "accelerating the ongoing shift of the Company's MedTech portfolio toward higher-growth and higher-margin markets." It isn't that DePuy Synthes is a bad business; it's just that it isn't growing as quickly, and it doesn't have as high profit margins as J&J's other medical device businesses. Johnson & Johnson: Smaller, but faster growing and more profitable Whether or not J&J sells DePuy Synthes to Apollo or spins the business off, the division is out the door. The move is in line with J&J's longer-term goal of becoming a leaner, more profitable company with a faster growth profile. While some investors prefer diversification, Wall Street is likely to reward J&J more for increased profitability and more rapid growth. If you own J&J, this is probably a good move, with the sale of DePuy Synthes offering an opportunity for a quicker, cleaner break. Should you buy stock in Johnson & Johnson right now? Before you buy stock in Johnson & Johnson, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $387,158 !* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,365,749 !* Now, it’s worth noting Stock Advisor’s total average return is 932 % — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor , and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of September 21, 2026. Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson and Kenvue. The Motley Fool has a disclosure policy .

Johnson & Johnson announced plans to spin off its orthopedics business in late 2025.

In early 2026, J&J was reported to be in talks with private equity firms about a sale.

In late 2026, J&J was reported to be in talks with Apollo on a $20 billion deal.

Wall Street goes through cycles in which companies buy assets to create diversified conglomerates, and then sell assets to streamline and focus. Right now, investors are rewarding companies for simplifying their operations and focusing their businesses. That's what Johnson & Johnson (NYSE: JNJ) has been doing. Here's what's been happening, why it's happening, and what it could mean for investors.

For many years, Johnson & Johnson was one of the most diversified healthcare companies an investor could own. Its business spanned over-the-counter consumer products, medical devices, and pharmaceuticals. The problem is that all of its divisions had very different business profiles. Diversification is something many investors cherish, but it can lead to slower decision-making and obscure the strong performance of faster-growing divisions.

Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »

Wall Street has a strong preference for growth, so J&J decided to break up the conglomerate. The first major move was the spin-off of Kenvue (NYSE: KVUE) in 2023. This company owns J&J's former over-the-counter healthcare brands. This business was more similar to a consumer staples company than a healthcare company, so it was a fairly logical move. Kenvue is now being acquired by consumer-staples giant Kimberly Clark (NASDAQ: KMB) , which is seeking to diversify its business.